ANXIOLYTIC AND ANTIDEPRESSANT TETRAHYDROBENZOTHIENOPYRIDINE DERIVATIVES

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, phenyl or phenyl C₁₋₄ alkyl wherein the phenyl moiety is optionally substituted by one or more C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, C₂₋₇ alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl or carboxy groups; R₂, R₃ and R₄ are independently selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, C₂₋₇ alkanoyl, trifluoromethyl, cyano, carbamoyl and carboxy, and phenyl or phenyl C₁₋₄ alkyl in which any phenyl moiety is optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, hydroxy, C₂₋₇ alkanoyl, chloro, fluoro, trifluoromethyl, nitro or amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl and carboxy; R₅ and R₆ are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, C₂₋₆ alkenyl, C₁₋₇ alkanoyl, C₁₋₆ alkylsulphonyl, di-(C₁₋₆ alkyl)amino C₁₋₆ alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C₁₋₄ alkyl, benzoyl, phenyl C₂₋₇ alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, CF₃, amino or carboxy, or R₅ and R₆ together are C₂₋₆ polymethylene optionally interrupted by oxygen or NR₈ wherein R₈ is hydrogen or C₁₋₆ alkyl optionally substituted by hydroxy; and -CO₂R₇ is a pharmaceutically acceptable ester group, are provided for use in the treatment or prophylaxis of CNS disorders, in particular anxiety or depression.

Description: This invention relates to compounds having pharmacological activity, to a process for their preparation, to compositions containing them and to their use in the treatment of mammals. EP-A-0 249 301 (Beecham Group plc) discloses a class of compounds having anxiolytic and/or anti-depressant activity which compounds are 4-amino-9H-pyrido[2,3-b]indole-3-carboxylate derivatives. I. Lalezari, Journal of Heterocyclic Chemistry, 16 , 603, (1979) describes the preparation of 4-aminothieno[2,3-b]pyridine-5-carboxylate derivatives of formula (A): wherein R a is hydrogen or ethyl; R b and R c are methyl, or R b and R c together are -(CH₂) n - where n is 3, 4 or 5. No pharmacological activity is attributed to compounds of formula (A). A class of compounds has now been discovered, which compounds have been found to have CNS activity, in particular anxiolytic and/or anti-depressant activity. Accordingly, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is a hydrogen, C₁₋₆ alkyl, phenyl or phenyl C₁₋₄ alkyl wherein the phenyl moiety is optionally substituted by one or more C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, C₂₋₇ alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl or carboxy groups; R₂, R₃ and R₄ are independently selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, C₂₋₇ alkanoyl, trifluoromethyl, cyano, carbamoyl and carboxy, and phenyl or phenyl C₁₋₄ alkyl in which any phenyl moiety is optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, hydroxy, C₂₋₇ alkanoyl, chloro, fluoro, trifluoromethyl, nitro or amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl and carboxy; R₅ and R₆ are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, C₂₋₆ alkenyl, C₁₋₇ alkanoyl, C₁₋₆ alkylsulphonyl, di-(C₁₋₆ alkyl)amino C₁₋₆ alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C₁₋₄ alkyl, benzoyl, phenyl C₂₋₇ alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C₁-₆ alkyl, C₁₋₆ alkoxy, CF₃, amino or carboxy, or R₅ and R₆ together are C₂₋₆ polymethylene optionally interrupted by oxygen or NR₈ wherein R₈ is hydrogen or C₁₋₆ alkyl optionally substituted by hydroxy; and R₇ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl or C₃₋₆ cycloalkyl-C₁₋₄ alkyl; for pharmaceutical use. By pharmaceutical use is meant the treatment or prophylaxis of disorders in mammals including humans. Compounds of formula (I) and their pharmaceutically acceptable salts have anxiolytic and/or antidepressant activity and are of particular use in the treatment or prophylaxis of CNS disorders, in particular anxiety or depression. Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of CNS disorders, in particular anxiety or depression. In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment or prophylaxis of CNS disorders, in particular anxiety or depression. The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral or parenteral administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, or injectable or infusable solutions or suspensions. Orally administrable compositions are generally preferred. Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants. For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of CNS disorders, such as anxiety or depression will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months. Within the above indicated dosage range, no adverse toxicological effects are indicated with the compounds of the invention. Alkyl moieties within the variables R₁ to R₆ are preferably C₁₋₃ alkyl, such as methyl, ethyl and n - and iso -propyl. Values for R₁ include hydrogen, methyl, ethyl, n - and iso -propyl, phenyl and benzyl. Preferably, R₁ is methyl. Values for R₂, R₃ and R₄ include hydrogen or C₁₋₄ alkyl. Preferably, two of R₂, R₃ and R₄ represent hydrogen, and more preferably R₂, R₃ and R₄ each represent hydrogen. Values for R⁵ and R⁶ include hydrogen, methyl, ethyl, n - and iso -propyl, n -, sec -, iso - and tert -butyl, n -, sec , iso - and neo -pentyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentyl-C₁₋₄ alkyl, cyclohexyl-C₁₋₄ alkyl and cycloheptyl-C₁₋₄ alkyl, where values for C₁₋₄ alkyl include methylene and ethylene, but-2-enyl, but-3-enyl, 1-methylprop-2-enyl, formyl, acetyl, propionyl, methylsulphonyl, 3-dimethylaminobutyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, benzyl, benzoyl, benzylcarbonyl and benzenesulphonyl, or R₅ and R₆ together form C₄ or C₅ polymethylene, -(CH₂)₂-O-(CH₂)₂- or -(CH₂)₂- NR₈-(CH₂)₂- where R₈ is preferably methyl. Preferably R₅ is hydrogen and R₆ is hydrogen or C₁₋₆ alkyl, for example methyl. There is a favoured group of compounds within formula (I) of formula (II) or a pharmaceutically acceptable salt thereof: wherein R₁, R₅, R₆ and R₇ are as defined in formula (I). Preferred values for R₁, R₅ and R₆ are as described under formula (I). There is a preferred group of compounds within formula (II) of formula (III) or a pharmaceutically acceptable salt thereof: wherein R₆′ is hydrogen or C₁₋₆ alkyl and R₁ and R₇ are as defined in formula (I). Preferred values for R₁ and R₆′ are as described for the corresponding variables in formula (I): The invention further provides novel compounds within formula (I), wherein the variable groups are as defined in formula (I) with the proviso that when R₁ is methyl and R₂, R₃, R₄, R₅ and R₆ are hydrogen, R₇ is other than ethyl. Such compounds are hereinafter referred to as compounds of formula (Ia). The compounds of the formula (I) can form acid addition salts with acids, such as the conventional pharmaceutically acceptable acids, for example, maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic. Suitable examples of pharmaceutical esters of the (CO₂R₇) of the compounds of formula (I) include C₁₋₆ alkyl esters, such as methyl, ethyl, n - and iso -propyl, n -, sec - and tert -butyl esters, C₂₋₆ alkenyl esters such as vinyl, prop-1-enyl, prop-2-enyl, 1-methylvinyl, but-1-enyl, but-3-enyl, 1-methylenepropyl and 1-methylprop-2-enyl, (in both their E and Z forms where stereoisomerism exists), C₂₋₆ alkynyl esters such as prop-2-ynyl, C₃₋₆ cycloalkyl esters and C₃₋₆ cycloalkyl-C₁₋₄ alkyl esters such as cyclopropylmethyl. Preferably the pharmaceutically acceptable ester is the methyl, ethyl, propyl, prop-2-enyl or prop-2-ynyl ester, i.e. R₇⁻ is methyl, ethyl, propyl, prop-2-enyl or prop-2-ynyl. It will be appreciated that the compounds of formula (I) in which R₅ or R₆ is hydrogen may exist tautomerically in more than one form. The invention extends to each of these forms and to mixtures thereof. Compounds of formula (I) may also form solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term "compound of formula (I)" also includes solvates thereof. A process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof comprises the reaction of a compound of formula (IV): with a compound of formula (V): wherein R₁′ is R₁ as defined in formula (I) or a group convertible thereto, R₂,R₃ and R₄ are as defined in formula (I), R₇′ is -CO₂R₇ as defined in formula (I) or an electron-withdrawing group convertible to -CO₂R₇, L is a leaving group and M is hydrogen or L and M together represent a bond, and Y is a group CN or COL₁, where L₁ is a leaving group; and thereafter, optionally or as necessary, when Y is a group COL₁, converting the resulting hydroxy group to a leaving group and reacting the latter with a compound HNR₅R₆, converting R₁′ when other than R₁ to R₁, converting R₇′ when other than -CO₂R₇ to -CO₂R₇, interconverting R₅ or R₆, and/or forming a pharmaceutically acceptable salt of the compound of formula (I). Suitable examples of the leaving group L include halogens, such as chloro and bromo, hydroxy, C₁₋₆ acyloxy such as acetoxy or C₁₋₆ alkoxy, such as methoxy or ethoxy, preferably methoxy. When L is hydroxy, it will be appreciated that the compound of formula (V) exists in more than one tautomeric form. The reaction of compounds of formulae (IV) and (V) comprises a condensation step followed by a cyclisation step, the acyclic enamine intermediate optionally being isolated before cyclisation. The condensation step may be carried out under conditions conventional for condensation reactions, at elevated temperatures in an inert solvent such as toluene, benzene, ethanol, pyridine, dimethylformamide or dioxan, optionally in the presence of a catalyst such as para-toluene-sulphonic acid, with water separation. The cyclisation of the enamine may also be carried out under conventional conditions, in the presence of a strong base such as an alkali metal alkoxide, for example sodium methoxide in a suitable solvent such as methanol, at elevated temperature, or in the presence of a Lewis acid such as ZnCl₂, SnCl₄ or CuOCOCH₃ in n -butyl acetate at elevated temperature. Suitable examples of groups R₇′ include the groups hereinbefore described for -CO₂R₇, CO₂Q where Q is a protecting group such as benzyl wherein the benzyl moiety is optionally substituted in the phenyl ring by one or two of halogen, CF₃, C₁₋₆ alkoxy, C₁₋₆ alkyl or nitro, or cyano and -CONR₉R₁₀ where R₉ and R₁₀ are independently selected from hydrogen, C₁₋₆ alkyl and phenyl or phenyl C₁₋₄ alkyl optionally substituted as described above for optional substituents in the phenyl ring of a benzyl ester, or together form a C₂₋₆ polymethylene chain optionally interrupted by oxygen or NR₁₁ wherein R₁₁ is hydrogen or C₁₋₆ alkyl, e.g. morpholino or piperazino. A protecting group Q may be removed by conventional hydrolysis or hydrogenolysis to yield the free acid which can then be esterified under conventional conditions by reaction with the appropriate alcohol R₇OH, optionally with prior conversion of the acid to the acid chloride by reaction with a suitable chlorinating agent such as thionyl chloride, or with an alkylating agent R₇X where X is a leaving group such as chloro, bromo or iodo, in the presence of a suitable base such as potassium carbonate. An intermediate amide may be hydrolysed to the free acid which can then be esterified as described above. An R₇′ cyano group may be converted under anhydrous conditions to an imino ester by reaction with the appropriate alcohol R₇OH and then hydrolysed to the group -CO₂R₇. Suitable examples of a leaving group L₁ when Y is COL₁, include hydroxy and, more preferably, alkoxy such as ethoxy or methoxy. The reaction of the compounds of formulae (IV) and (V) gives a resulting compound having an hydroxy group in the 4-position of the pyridine ring. The hydroxy group may be converted to a leaving group such as those defined above for L, preferably halo such as chloro, by reaction with a halogenating agent such as phosphorus oxychloride or phosphorus oxybromide. The leaving group may be displaced by the compound HNR₅R₆ under conventional conditions for nucleophilic aromatic displacements, at elevated temperatures in an inert solvent such as toluene, methanol, ethanol, pyridine, dimethylformamide or dioxan. Alternatively, the reaction may be carried out in neat HNR₅R₆ which functions as the solvent. Conversion of R₅ and R₆ hydrogen or other R₅/R₆ may be carried out in accordance with conventional procedures for the alkylation or acylation of the primary amine. Acylation may be carried out by reaction with the appropriate acyl halide. However, R₅/R₆ other than hydrogen or acyl groups are preferably introduced via the route in which Y is COL₁ in the compound of formula (IV), by displacement of the leaving group with the compound HNR₅R₆ as discussed above. For the preparation of compounds of formula (I) in which R₁ is hydrogen, the compound of formula (V) may be used in which L and M together represent a bond or L is hydroxy and M is hydrogen, and R₁′ is a C₁₋₆ alkoxycarbonyl group. The reaction with the compound of formula (IV) may then be followed by a decarboxylation step to give R₁ hydrogen. Alternatively, a compound of formula (V) may be used in which L is a leaving group and R₁′ is hydroxy. In the resulting compound, the R₁′ hydroxy may be converted to hydrogen by first replacing it by chloro by conventional chlorination with a chlorinating agent such as phosphorus oxychloride followed by reductive dehalogenation under conventional conditions, for example zinc in acetic acid. Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or derivative. It will be appreciated that the present invention also provides a process for the preparation of the novel compounds of formula (Ia). A class of intermediates comprises compounds of formula (IV) or a salt thereof: wherein R₁′ is as defined in formula (V), R₇″ is R₇′ as defined in formula (V), X is NH₂, OH or chloro and R₂, R₃ and R₄ are as defined in formula (IV), provided that when X is NH₂ and R₁′ is R₁, R₇″ is other than -CO₂R₇, when X is NH₂, R₁′ is methyl and R₂, R₃, and R₄ are hydrogen, R₇″ is other than CO₂H, when X is NH₂ and R₁′, R₂, R₃ and R₄ are hydrogen, R₇″ is other than cyano, and when X is OH and R₁′, R₂, R₃ and R₄ are hydrogen, R₇″ is other than CO₂H or CO₂C₂H₅. The compound of formula (VI) in which R₇″ is CO₂H, X is NH₂, R₁′ is methyl and R₂, R₃ and R₄ are hydrogen has been described by I. Lalezari, J. Het. Chem., 16 , 603, (1979). The compounds of formula (VI) in which R₇″ is CO₂H and CO₂C₂H₅, X is OH and R₁′, R₂, R₃ and R₄ are hydrogen have been described in Belgian Patent 817950 (Takeda). The compound of formula (VI) in which R₇″ is cyano, X is NH₂ and R₁′, R₂, R₃ and R₄ are hydrogen has been described by K. Gewald et al ., Monatsh Chem., 1070, 110(5), 1189. Novel compounds of formula (VI) also form part of the invention. Compounds of formulae (IV) and (V) are known or can be prepared by analogous processes to those used for preparing known compounds. In particular, compounds of formula (IV) may be prepared using procedures similar to that in K. Gewald et al .; Chem. Ber. 1966, 94. The compound of formula (IV) in which R₂, R₃ and R₄ are hydrogen and Y is ethoxycarbonyl is commercially available. The compound of formula (V) in which R₁′ is phenyl, M is hydrogen, L is ethoxy and R₇′ is ethoxycarbonyl is described by V.L. Leighton, American Chem. Journal, 1898, 20 , 133. The following Examples illustrate the preparation of pharmacologically active compounds of the invention. Examples 1 to 5, 7 and 8 illustrate the preparation of novel compounds of formula (Ia). The following Descriptions illustrate the preparation of intermediates to the compounds of the present invention. Description 1 2-Amino-3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophene (D1) The title compound was prepared using a procedure similar to that in K. Gewald et al . ; Chem. Ber. 1966, 94 (67% yield; m.p. 146-7°C). Description 2 4-Hydroxy-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester (D2) Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5.0g; 22mM) and ethyl 3-ethoxycrotonate (4.17g; 26.4mM) were converted into the title compound (5.8g; 90%). m.p. 135-6°. Found: C, 61.58; H, 5.86; N, 4.72 C₁₅H₁₇NO₃S requires C, 61.83; H, 5.88; N, 4.81% Description 3 4-Chloro-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester (D3) A solution of D2 (10g; 34.4 mM) in phosphorus oxychloride (100ml) was heated under reflux for 4h and then evaporated to dryness. The residue was partitioned between aqueous sodium bicarbonate and dichloromethane and the organic phase dried (Na₂SO₄). Evaporation in vacuo followed by flash chromatography on silica gave the title compound (6.75g; 63%). Example 1 4-Amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, methyl ester, (E1) A solution of the amino nitrile D1 (7.27g; 41mM) and methyl β-methoxycrotonate (5.34g; 41mM) in toluene (150 ml) was heated at reflux for 96h. The reaction mixture was cooled, filtered and treated with a 1M solution of sodium methoxide in methanol (42ml). The resulting dark solution was refluxed under nitrogen for 5h. The reaction mixture was cooled and shaken with brine (150ml). The organic phase was separated, then dried over anhydrous sodium sulphate and evaporated in vacuo to give the title compound E1 as an off-white solid (8.75g; 78%). m.p. 185-93° (from methanol) NMR (CDCl₃) δ: 1.82 (4H, m) 2.64 (3H, s), 2.85 (4H, m), 3.85 (3H, s), 6.46 (2H, s, ex D₂O). Found: C, 60,60; H, 5.69; N,10.02 C₁₄H₁₆N₂O₂S requires C, 60.85; H, 5.84; N 10.14% Found M⁺ 276.0938 C₁₄H₁₆N₂O₂S requires 276.0932 Example 2 4-Amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propenyl ester (E2) The title compound E2 was prepared from the methyl ester E1 by hydrolysis using aqueous ethanolic sodium hydroxide at reflux followed by alkylation with allyl bromide using potassium carbonate in dimethylformamide. m.p. 125-6° (from methanol) Found: C, 63.33; H, 6.09; N, 9.16 C₁₆H₁₈N₂O₂S requires C, 63.55; N, 6.00; N, 9.26% Example 3 4-Amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propynyl ester (E3) The title compound E3 was prepared from the methyl ester E1 and 2-propynyl bromide using a method similar to that of Example 2. m.p 158-60° (from methanol). Found: C, 64.10; H, 5.29; N, 9.23 C₁₆H₁₆N₂O₂S requires C, 63.98; H, 5.37; N, 9.33% Example 4 4-Amino-2-phenyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester (E4) The title compound was prepared in 20% overall yield from D1 and ethyl β-ethoxycinnamate using a method similar to that of Example 1. m.p. 54-6° (from ethanol). Found: C, 67.63; H, 5.87; N, 7.80 C₂₀H₂₀N₂O₂S requires C, 68,16; H, 5.72; N, 7.95% Example 5 4-Amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, isopropyl ester (E5) The title compound was prepared from the ethyl ester (E6) and 2-iodopropane using a method similar to that of Example 2. m.p. 113-115°C (from ether). Found: C, 63.10; H, 6.48; N, 9.23 C₁₆H₂₀N₂O₂S requires C, 63.13; H, 6.62; N, 9.20% Example 6 4-Amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3,-b]pyridine-3-carboxylic acid, ethyl ester (E6) The title compound was prepared in 22% overall yield from D1 and ethyl 3-ethoxycrotonate using a method similar to that described in Example 1. m.p. 133-136°C (from ethanol). Found: C, 62.48; H, 6.34; N, 9.61 C₁₅H₁₈N₂O₂S requires C, 62.04; H, 6.25; N, 9.65%. Example 7 2-Methyl-4-methylamino-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester (E7) The title compound was prepared in 20% yield from D3 and methylamine using an autoclave followed by chromatography on Kieselgel 60 in dichloromethane. m.p. 110-112° (from ethyl acetate-petrol). Found: C, 62.85; H, 6.58; N, 9.21 C₁₆H₂₀N₂O₂S requires C, 63.13; H, 6.62; N, 9.20%. NMR (CDCl₃) δ: 1.43 (3H, t, J=7Hz), 1.80-1.97 (4H, m), 2.50 (3H, s), 2.75-2.85 (2H, m), 2.93 (3H, d, J=5Hz), 2.96-3.03 (2H, m), 4.40 (2H, q, J=7Hz), 5.07-5.28 (1H, br). Example 8 2-Methyl-4-methylamino-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propynyl ester (E8) The title compound was prepared from D3 and methylamine in an autoclave followed by hydrolysis and esterification with propargyl bromide using a method similar to that of Example 2. m.p. 108-9°C. Pharmacological Data Geller-Seifter Procedure Potential anxiolytic properties have been evaluated using the Geller-Seifter procedure based on that original described by Geller and Seifter, (1960) Psychopharmacologia, 1, 482-492. This procedure has been shown to be selective for drugs with anxiolytic properties (Cook and Sepinwall, (1975) "Mechanism of Action of Benzodiazepines" ed. Costa, E. and Greengard, P., Raven Press, New York, pp. 1-28). Rats are trained on a variable interval 30 sec schedule (VI30) to press a lever in order to obtain food reward. The 5 min sessions of the VI30 schedule alternate with 2-5 min of a schedule (FR5) in which every 5th lever press is followed by presentation of a food pellet paired with a 0.5 sec mild footshock. The total study lasts approximately 30 mins. Rats typically respond with high rates of lever pressing under the VI30 schedule and low response rates under the FR5 'conflict' session. Anxiolytic drugs increase the suppressed response rates of rats in 'conflict' session. Drugs are administered intraperitoneally or orally to groups of 3-8 rats 30 min before testing. The results are expressed as the percentage increase in square root of the total number of lever presses in the FR5 'conflict' session. Square root transformation is necessary to normalise the data for statistical analysis using parametric methods (ANOVA). Testing Results The activity of the following compounds in the above test is detailed in the following Table. Compound dose mg/kg increase in responding in the 'conflict' session Example 1 (E1) 50 p.o. +93% Example 2 (E2) 20 p.o. +21% Example 3 (E3) 20 p.o. +56% Example 4 (E4) 20 p.o. +14%

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, phenyl or phenyl C₁₋₄ alkyl wherein the phenyl moiety is optionally substituted by one or more C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, C₂₋₇ alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl or carboxy groups; R₂, R₃ and R₄ are independently selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, C₂₋₇ alkanoyl, trifluoromethyl, cyano, carbamoyl and carboxy, and phenyl or phenyl C₁₋₄ alkyl in which any phenyl moiety is optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, hydroxy, C₂₋₇ alkanoyl, chloro, fluoro, trifluoromethyl, nitro or amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl and carboxy; R₅ and R₆ are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, C₂₋₆ alkenyl, c₁₋₇ alkanoyl, C₁₋₆ alkylsulphonyl, di-(C₁₋₆ alkyl)amino C₁₋₆ alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C₁₋₄ alkyl, benzoyl, phenyl C₂₋₇ alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, CF₃, amino or carboxy, or R₅ and R₆ together are C₂₋₆ polymethylene optionally interrupted by oxygen or NR₈ wherein R₈ is hydrogen or C₁₋₆ alkyl optionally substituted by hydroxy; and R₇ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynl, C₃₋₆ cycloalkyl or C₃₋₆ cycloalkyl-C₁₋₄ alkyl; for pharmaceutical use. A compound of formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are as defined for formula (1) in claim 1, with the proviso that when R₁ is methyl and R₂, R₃, R₄, R₅ and R₆ are hydrogen, R₇ is other than ethyl. A compound according to claim 2 wherein R₁ is hydrogen, C₁₋₃ alkyl, phenyl or benzyl. A compound according to any one of claims 2 or 3, wherein R₂, R₃ and R₄ are each hydrogen. A compound according to any one of claims 2 or 4 wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl. A compound according to any one of claims 2 to 5, wherein R₁ is methyl or phenyl, R₂, R₃ and R₄ are each hydrogen, R₅ and R₆ are independently hydrogen or methyl and R₇ is methyl, ethyl, propyl, prop-2-enyl or prop-2-ynyl. 4-Amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno-[2,3-b] pyridine-3-carboxylic acid, methyl ester; 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propenyl ester; 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propynyl ester; 4-amino-2-phenyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester; 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, isopropyl ester; 2-methyl-4-methylamino-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester; or 2-methyl-4-methylamino-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propynyl ester. A process for the preparation of a compound of formula (1a) as defined in any one of claims 2 to 7 or a pharmaceutically acceptable salt thereof, which process comprises the reaction of a compound of formula (IV): with a compound of formula (V): wherein R₁' is R₁ as defined in formula (I) or a group convertible thereto, R₂,R₃ and R₄ are as defined in formula (I), R₇' is -CO₂R₇ as defined in formula (I) or an electron-withdrawing group convertible to -CO₂R₇, L is a leaving group and M is hydrogen or L and M together represent a bond, and Y is a group CN or COL₁, where L₁ is a leaving group; and thereafter, optionally or as necessary, when Y is a group COL₁, converting the resulting hydroxy group to a leaving group and reacting the latter with a compound HNR₅R₆, converting R₁' when other than R₁ to R₁, converting R₇' when other than -CO₂R₇ to -CO₂R₇, interconverting R₅ or R₆, and/or forming a pharmaceutically acceptable salt of the compound of formula (Ia). A compound of formula (VI) or a salt thereof: wherein R₁' is as defined in formula (V), R₇'' is R₇' as defined in formula (V), X is NH₂, OH or chloro and R₂, R₃ and R₄ are as defined in formula (IV), provided that when X is NH₂ and R₁' is R₁, R₇'' is other than -CO₂R₇, when X is NH₂, R₁' is methyl and R₂, R₃, and R₄ are hydrogen, R₇'' is other than CO₂H, when X is NH₂ and R₁', R₂, R₃ and R₄ are hydrogen, R₇'' is other than cyano, and when X is OH and R₁', R₂, R₃ and R₄ are hydrogen, R₇'' is other than CO₂H or CO₂C₂H₅. 4-Chloro-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno-[2,3-b]pyridine-3-carboxylic acid, ethyl ester. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. A compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of CNS disorders, in particular anxiety or depression. The use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of CNS disorders, in particular anxiety or depression. Claims for the following Contracting State : ES A process for the preparation of pharmaceutical composition which comprises the admixture of a unit dose of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, phenyl or phenyl C₁₋₄ alkyl wherein the phenyl moiety is optionally substituted by one or more C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, C₂₋₇ alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl or carboxy groups; R₂, R₃ and R₄ are independently selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, C₂₋₇ alkanoyl, trifluoromethyl, cyano, carbamoyl and carboxy, and phenyl or phenyl C₁₋₄ alkyl in which any phenyl moiety is optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylthio, hydroxy, C2-7 alkanoyl, chloro, fluoro, trifluoromethyl, nitro or amino optionally substituted by one or two C₁₋₆ alkyl groups or by C₂₋₇ alkanoyl, cyano, carbamoyl and carboxy; R₅ and R₆ are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, C₂₋₆ alkenyl, C₁₋₇ alkanoyl, c₁₋₆ alkylsulphonyl, di-(C₁₋₆ alkyl)amino C₁₋₆ alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C₁₋₄ alkyl, benzoyl, phenyl C₂₋₇ alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, CF₃, amino or carboxy, or R₅ and R₆ together are C₂₋₆ polymethylene optionally interrupted by oxygen or NR₈ wherein R₈ is hydrogen or C₁₋₆ alkyl optionally substituted by hydroxy; and R₇ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl or C₃₋₆ cycloalkyl-C₁₋₄ alkyl; with a pharmaceutically acceptable carrier at ambient temperature and atmospheric pressure. A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are as defined for formula (I) in claim 1, with the proviso that when R₁ is methyl and R₂, R₃, R₄, R₅ and R₆ are hydrogen, R₇ is other than ethyl, which process comprises the reaction of a compound of formula (IV): with a compound of formula (V): wherein R₁' is R₁ as defined in formula (I) or a group convertible thereto, R₂,R₃ and R₄ are as defined in formula (I), R₇' is -CO₂R₇ as defined in formula (I) or an electron-withdrawing group convertible to -CO₂R₇, L is a leaving group and M is hydrogen or L and M together represent a bond, and Y is a group CN or COL₁, where L₁ is a leaving group; and thereafter, optionally or as necessary, when Y is a group COL₁, converting the resulting hydroxy group to a leaving group and reacting the latter with a compound HNR₅R₆, converting R₁' when other than R₁ to R₁, converting R₇' when other than -CO₂R₇ to -CO₂R₇, interconverting R₅ or R₆, and/or forming a pharmaceutically acceptable salt of the compound of formula (Ia). A process according to claim 2 wherein R₁ is hydrogen, C₁₋₃ alkyl, phenyl or benzyl. A process according to any one of claims 2 or 3 wherein R₂, R₃ and R₄ are each hydrogen. A process according to any one of claims 2 to 4 wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl. A process according to any one of claims 2 to 5 wherein R₁ is methyl or phenyl, R₂, R₃ and R₄ are each hydrogen, R₅ and R₆ are independently hydrogen or methyl and R₇ is methyl, ethyl, propyl, prop-2-enyl or prop-2-ynyl. A process according to any one of claims 2 to 6 wherein the compound of formula (Ia) is: 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, methyl ester; 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propenyl ester; 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, 2-propynyl ester; 4-amino-2-phenyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester; 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-b]pyridine-3-carboxylic acid, isopropyl ester; 2-methyl-4-methylamino-5,6,7,8-tetrahydrobenzo[b]-thieno[2,3-b]pyridine-3-carboxylic acid, ethyl ester; or 2-methyl-4-methylamino-5,6,7,8-tetrahydrobenzo[b]thieno [2,3-b]pyridine-3-carboxylic acid, 2-propynyl ester. The use of a compound of formula (I) as defined in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of CNS disorders, in particular anxiety or depression.

Inventors: FORBES, IAN THOMSON, JOHNSON, CHRISTOPHER NORBERT, THOMPSON, MERVYN
Applicants: BEECHAM GROUP PLC
Application year: 1989
Main classification: C07D495
IPC codes: A61P25, A61K31, C07D333, C07D495